Survival After Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma: Does Only a Complete Pathologic Response Matter?
Objective:
To evaluate whether pCR exclusively defines major pathologic response to treatment with improved survival.
Summary Background Data:
pCR after trimodality therapy for EAC is infrequent but associated with improved prognosis. Yet most clinical trials and correlative studies designate pCR as the primary endpoint.
Methods:
We analyzed our prospectively maintained database for patients who underwent trimodality therapy for locally advanced esophageal adeno-carcinoma between 1995 and 2017. Overall survival (OS) was examined by percentage TR in the primary tumor bed and pathologic nodal stage (ypN0) using Kaplan-Meier plots. Optimal thresholds of TR for differentiating patients in terms of OS were investigated with descriptive plots using restricted cubic spline functions; associations were quantified using Cox multivariable analysis.
Results:
Among 788 patients, median follow-up was 37.5 months (range, 0.4210.6); median OS was 48.3 months (95% CI, 42.2–58.8). Absence of residual nodal disease was independently associated with improved survival (P 90% TR and ypN0. This has meaningful implications for future clinical trials and correlative studies.
Source: Annals of Surgery - Category: Surgery Tags: Original Articles Source Type: research
More News: Adenocarcinoma | Cancer & Oncology | Carcinoma | Clinical Trials | Databases & Libraries | Esophagus Cancer | Study | Surgery